Crowdstrike Holdings Inc vs Heron Therapeutics Inc — how do they compare? Crowdstrike Holdings Inc trades at $272.05 (market cap $269.31B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: Crowdstrike Holdings Inc is far larger — about 3959.9× Heron Therapeutics Inc's market cap, and Crowdstrike Holdings Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crowdstrike Holdings Inc for 97 Days and Heron Therapeutics Inc for 35 Days on average.
| CRWD | HRTX | |
|---|---|---|
Market Cap | $269.31B | $68.01M |
Volume | 9,381,560 | 1,891,941 |
Sector | Technology | Health |
52-Week High | $278.86 | $1.49 |
52-Week Low | $87.56 | $0.27 |
Typical Hold Time | 97 Days | 35 Days |
Enterprise Value | $265.11B | $174.75M |
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $272.00, up 2.47% today and near its all-time highs, with strong technical momentum and bullish moving average signals. The company demonstrates impressive revenue growth, reaching $3.95 billion in 2025, though profitability remains volatile with a net income margin of -0.49%. Recent quarterly earnings have consistently beaten expectations, and analyst sentiment remains overwhelmingly positive with 76% buy ratings.
The outlook for CRWD remains favorable given strong cybersecurity demand and AI-driven growth opportunities, though elevated valuation multiples and competitive pressures present risks. Wall Street's consensus price target of $235.74 suggests potential downside from current levels, but continued execution on revenue growth and margin expansion could support further upside.
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →